Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising the Swiss drugmaker’s bet on the U.S. genomic profiling group’s ability to personalize cancer care.
Watertown, Mass.-based Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage study that showed a significant reduction of serum uric acid at 12 weeks.
Madrigal Pharmaceuticals’ shares more than doubled after mid-stage trial data showed the company’s lead drug reduced liver fat in patients with fatty liver disease.
China has overtaken the United States in healthy life expectancy at birth for the first time, according to World Health Organization data.
Novartis’ foray into digital technology intensified as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies.
Roche and its subsidiaries are ramping up treatment options for multiple sclerosis. In April, the company acquired a regenerative therapy program for MS from Inception Sciences. Now, Roche’s Genentech announced new data showcasing the efficacy of Ocrevus in relapsing multiple sclerosis (RMS).
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.
U.S. FDA staff flagged concerns about potentially fatal blood clots from higher doses of a rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp.
The U.S. FDA accepted Alkermes’ New Drug Application (NDA) for ALKS 5461, a treatment for major depressive disorder
Blockchain is best known as being linked to the cryptocurrency Bitcoin. For those a bit more in the know, it is the underlying data infrastructure that allows Bitcoin to work.
Israel will invest nearly 1 billion shekels ($287 million) in a project to make data about the state of health of its population available to researchers and private companies, Prime Minister Benjamin Netanyahu said.
Alzheon, based in Framingham, Massachusetts, filed with the U.S. Securities and Exchange Commission to launch an initial public offering (IPO).
Israel’s Medial EarlySign, whose machine-learning based technology is meant to help improve patient management, said on Tuesday it raised $30 million, bringing its total funding to $50 million.
Beacon Healthcare Communications named Amy Whitcomb as Director of Multi-Channel Marketing in response to growing client needs for integrated multi-channel marketing solutions to drive brand campaign performance.
Fast Company recently published The World’s 50 Most Innovative Companies 2018, topping off its edition of the top 350 most innovative companies. Here is a look at the life science companies that made the list.
U.S. drug developer Aimmune Therapeutics Inc.’s peanut allergy drug met the main goal of an eagerly awaited late-stage study.
Roche Holding will buy the rest of U.S. cancer data company Flatiron Health that the Swiss drugmaker does not already own for $1.9 billion to speed development of cancer medicines.
Statement from FDA Commissioner Scott Gottlieb, M.D. on the efficacy of the 2017-2018 influenza vaccine
Seasonal flu has been widespread in 2018, impacting millions of people across the country. It has been an especially challenging season, with high rates of hospitalization for both influenza and its complications, which include pneumonia and the exacerbation of chronic conditions such as asthma and congestive heart failure. Many schools have closed in an attempt to control the spread of the illness and doctor’s offices are packed with patients seeking diagnosis and antiviral treatment.
At the Leerink Healthcare Conference, Biogen chief medical officer Al Sandrock shook up investors by saying the company added 510 more patients to its clinical trial of aducanumab in Alzheimer’s disease.
A combination of experimental drugs from Array BioPharma Inc. kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late-stage study.